title: Bradycardia and B-type natriuretic peptide.
abstract: Bradycardia and loss of atrioventricular synchrony can result in increased natriuretic peptide secretion due to increased cardiac wall tension. Antihypertensive beta-blocker therapy has been shown to cause elevated natriuretic peptide levels, as well as to increase the frequency of atrial fibrillation in hypertensive patients. The measurement of natriuretic peptides might help solve the clinical challenge of predicting the patients with high risk for beta-blocker induced atrial fibrillation.
authors.forename: Tímea
authors.initials: T
authors.lastname: Kováts
authors.forename: János
authors.initials: J
authors.lastname: Tomcsányi
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000009:adverse effects; D001281:Atrial Fibrillation / Q000097:blood* / Q000139:chemically induced / Q000453:epidemiology*; D001919:Bradycardia / Q000097:blood* / Q000453:epidemiology*; D006801:Humans; D020097:Natriuretic Peptide, Brain / Q000097:blood*; D011237:Predictive Value of Tests; D012307:Risk Factors
chemical_list: D000319:Adrenergic beta-Antagonists; D020097:Natriuretic Peptide, Brain